Skip to main content
evidena care

Safety

Cannabis not suitable for: contraindications and caution

For psychosis, pregnancy and breastfeeding, heart disease, adolescence and addiction, the product information and studies advise against it or urge caution.

Key points

  • The Swiss product information for Sativex lists as contraindications, among others, psychosis or schizophrenia in your own or family history, suicidal thoughts, pregnancy and breastfeeding.
  • In people with psychosis, continued cannabis use was associated with more relapses and longer hospital stays in a meta-analysis.
  • THC can affect pulse and blood pressure. Particular caution is needed with cardiovascular disease; the evidence comes mainly from observational studies.
  • In adolescents and with a history of addiction, the risks are higher. The decision on therapy is always made by the doctor after an assessment.

Medical cannabis is not suitable for everyone. The Swiss product information for Sativex, a ready-made cannabis medicine authorised in Switzerland, lists as contraindications, among others, suicidal thoughts, psychosis or schizophrenia in your own or family history, other significant psychiatric disorders, and pregnancy and breastfeeding.1

In addition, there are situations in which studies advise particular caution: cardiovascular disease, adolescence and addiction. Whether therapy is an option for you is decided by your doctor after an assessment. This article explains why these points are asked about.5,7,8

Contraindications according to the Sativex product information

In Switzerland, Sativex is authorised as an add-on therapy for moderate to severe spasticity in multiple sclerosis when other antispastic medicines are insufficiently effective. The product information lists the following contraindications:1

  • suicidality or suicidal thoughts
  • known or suspected schizophrenia or other psychosis, including in the family history
  • history of other significant psychiatric disorder, except depression associated with MS
  • pregnancy and breastfeeding
  • reproduction: women and men should prevent pregnancy during therapy and for up to three months afterwards

For other cannabis medicines, such as magistral preparations from the pharmacy, there is no separate product information. Doctors therefore orient themselves by this information and the study evidence. The following sections summarise it.

Situation Classification Main reason
Psychosis, schizophrenia, also in the family contraindication according to product information THC can trigger or worsen psychotic symptoms
Suicidal thoughts contraindication according to product information risk of deterioration
Pregnancy and breastfeeding contraindication according to product information possible consequences for the child
Cardiovascular disease careful weighing up effect on pulse and blood pressure
Adolescence great restraint brain still developing
Addiction careful weighing up higher risk of dependence

Psychosis and schizophrenia: the most important contraindication

The link between cannabis and psychosis has been well studied. A meta-analysis of ten studies with over 66,000 people found a dose-response relationship: in the heaviest users, the risk of schizophrenia and other psychosis-related outcomes was about 3.9 times as high as in non-users. The authors note that this does not clearly prove a causal relationship.2

In people who already have psychosis, the picture is even clearer. In a meta-analysis of 24 studies with over 16,000 participants, people who continued to use cannabis after the onset of psychosis had more relapses than non-users and people who had stopped, and longer hospital stays than non-users.3

These studies mainly concern recreational use, often with THC-rich products. But they show why the product information lists even a suspected psychosis in the family as a reason for exclusion. How doctors weigh things up with other pre-existing mental illnesses is explained in the article Cannabis medicine with a pre-existing mental illness.1

Pregnancy and breastfeeding: cannabis not suitable

The Sativex product information lists pregnancy and breastfeeding as a contraindication. It also requires women and men to prevent pregnancy during therapy and for up to three months afterwards.1

A meta-analysis of 24 observational studies found, with cannabis use during pregnancy, a higher rate of anaemia in the mother, a lower birth weight and more frequent transfer of the newborn to intensive care. The authors conclude that cannabis during pregnancy may increase the risk of adverse outcomes for mother and child.4 The pilot trials on recreational use also expressly exclude pregnant and breastfeeding women.9

If you are planning a pregnancy or have become pregnant, talk to your doctor immediately. Do not stop other medicines without consulting them. More on this in the article Cannabis and pregnancy.

Cardiovascular disease: caution with THC

THC can affect pulse and blood pressure. In a scientific statement, the American Heart Association states that cannabis may have therapeutic benefits, but hardly for the heart. Many of the concerning health consequences, by contrast, concern cardiovascular disease, and the route of intake may play a role.5

In a large US population survey with over 434,000 adults, daily cannabis use was associated with higher odds of heart attack and stroke, even in people who had never smoked tobacco.6 This study is a cross-sectional survey with self-reported data. It shows an association, not proof of cause and effect.

If you have coronary heart disease, heart rhythm disorders or poorly controlled high blood pressure, or have had a heart attack or stroke, your doctor must weigh benefits and risks particularly carefully.5,6 If you take blood pressure medication, you will find more in the article Cannabis and blood pressure medication. Never stop blood pressure medication without consulting your doctor; stopping abruptly can be dangerous.

Adolescents and young adults

The Sativex product information describes use in adults.1 Particular restraint applies to adolescents. A meta-analysis of eleven longitudinal studies with over 23,000 people found: those who used cannabis before the age of 18 had a higher risk of depression (odds ratio 1.37) and suicidal thoughts (1.50) as young adults. For anxiety disorders, the association was not significant. The authors assess the individual risk as moderate to low.7

The pilot trials on recreational use also exclude minors.9 Treating children and adolescents with cannabis medicines is a decision for specialised doctors in individual cases. This article gives no guidance on this.

History of addiction

Cannabis can be addictive. In a large US population study, the estimated probability of developing cannabis dependence over a lifetime after first use was 8.9 per cent. People with other mental illnesses or another dependence had a higher risk of transition to dependence.8

A past or existing dependence on alcohol, opioids, benzodiazepines or other substances does not automatically rule out therapy. It does, however, require careful weighing up and closer monitoring. If you already take opioids or benzodiazepines, never stop them abruptly and never without medical supervision. How doctors assess these combinations is explained in the article Cannabis and benzodiazepines.

Other situations that are assessed

Besides the major groups, the doctor asks about further points:

  • Liver: The Sativex product information does not recommend use in moderate or severe liver impairment because data on the accumulation of THC and CBD are lacking.1
  • Interactions: Other medicines that cause drowsiness can increase the effect of THC. Bring a complete list of your medicines.
  • Work and road traffic: If you drive vehicles or operate machinery, you must discuss this with your doctor.
  • Common side effects: Dizziness, tiredness and dry mouth are described in the article Side effects of medical cannabis.

How it works at evidena

At evidena, the doctor decides after an assessment whether therapy with cannabis medicines is an option for you. Pre-existing conditions, family history, pregnancy and current medicines are asked about. If a prescription is issued, it must be filled at a pharmacy within one month. As a rule, the prescribed quantity covers one month, in justified cases at most three months of treatment.10

You can book an appointment at portal.evidena.care/appointments. We answer questions via WhatsApp or at info@evidena.care.

Conclusion

According to the Sativex product information, clear contraindications are psychosis, including in the family, suicidal thoughts, significant psychiatric disorders, and pregnancy and breastfeeding.1 With heart disease, in adolescence and with addiction, careful medical weighing up is necessary. More on risks can be found in the Safety section.

Frequently asked questions

Who is medical cannabis not suitable for?

According to the Sativex product information, among others for people with psychosis or schizophrenia in their own or family history, with suicidal thoughts and during pregnancy and breastfeeding. Great caution is needed with heart disease, adolescents and addiction.

May I take cannabis if someone in my family has schizophrenia?

The Sativex product information lists a known or suspected family history of schizophrenia or other psychoses as a contraindication. Be sure to mention this during the assessment.

Is cannabis permitted during pregnancy?

No, the Sativex product information lists pregnancy and breastfeeding as a contraindication. In a meta-analysis, cannabis use during pregnancy was associated with lower birth weight.

I have heart disease. Is cannabis ruled out?

Not automatically, but your doctor must weigh the risk carefully. THC can affect pulse and blood pressure, and observational studies show associations with heart attack and stroke.

What if I already take other medicines?

Do not change or stop any medicines yourself. Discuss all medicines with your doctor so that interactions can be checked.

Your situation is individual

Discuss your questions with a doctor.

Book a consultation

Sources

  1. Fachinformation Sativex, Rubriken «Indikation» und «Kontraindikation», Compendium (accessed 13 November 2026)
  2. Marconi A et al. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016;42(5):1262-9. doi:10.1093/schbul/sbw003
  3. Schoeler T et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(3):215-25. doi:10.1016/S2215-0366(15)00363-6
  4. Gunn JK et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. doi:10.1136/bmjopen-2015-009986
  5. Page RL 2nd et al. Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2020;142(10):e131-e152. doi:10.1161/CIR.0000000000000883
  6. Jeffers AM et al. Association of Cannabis Use With Cardiovascular Outcomes Among US Adults. J Am Heart Assoc. 2024;13(5):e030178. doi:10.1161/JAHA.123.030178
  7. Gobbi G et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(4):426-434. doi:10.1001/jamapsychiatry.2018.4500
  8. Lopez-Quintero C et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120-30. doi:10.1016/j.drugalcdep.2010.11.004
  9. Verordnung über Pilotversuche nach dem Betäubungsmittelgesetz (BetmPV), SR 812.121.5, Art. 14, Fedlex (accessed 13 November 2026)
  10. Betäubungsmittelkontrollverordnung (BetmKV), SR 812.121.1, Art. 47, Stand am 23. Januar 2023, Fedlex (accessed 13 November 2026)

Written by evidena.care editorial team · Published 13 November 2026 · Reviewed 13 November 2026

This article is general information and does not replace medical advice. Whether cannabis therapy is an option for you is decided by a doctor in a personal consultation.